Investing.com - Erytech Pharma ADR reported on Monday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Erytech Pharma ADR announced earnings per share of $-0.353 on revenue of $25.77M. Analysts polled by Investing.com anticipated EPS of $-0.350 on revenue of $2.83M.
Erytech Pharma ADR shares are down 72.34% from the beginning of the year and are trading at $0.650 , down-from-52-week-high.
Erytech Pharma ADR follows other major Healthcare sector earnings this month
Erytech Pharma ADR's report follows an earnings beat by Eli Lilly on November 1, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
AbbVie had beat expectations on October 28 with third quarter EPS of $3.66 on revenue of $14.81B, compared to forecast for EPS of $3.58 on revenue of $14.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar